【2022 ESMO】Breaking the cocoon into a butterfly, born to the new Professor Wang Zhijie: EGFR ex20ins non-small cell lung cancer treatment field adds a new evidence!

With the development of precision medicine, the treatment of non-small cell lung cancer (NSCLC) mutant with epidermal growth factor receptor (EGFR) mutation has made a huge leap forward, and the chronic disease management model of patients with 19 exon deletions (19 del) and 21 exon (21 L858R) mutations in NSCLC is "from ideal to reality"

Expert profile

Professor Wang Zhijie

• Chief Physician, Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences

• He has published more than 30 SCI papers as correspondent/first authors (including co-authors), including Lancet resp med, JCO, JAMA Oncol, PNAS, Sci Advs, Cancer res, Clin cancer res, JTO and other journals

  
  

• He was selected as a young top-notch talent of the national "Ten Thousand People Plan" and a rising star of science and technology in

  
  

• Author of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer

• Member of the National Antineoplastic Clinical Application Monitoring Committee

• Member of the Expert Committee on Quality Control of Lung Cancer of the National Center for Quality Control of Oncology

• Director of the Chinese Society of Clinical Oncology (CSCO).

  
  

• Member of the Standing Committee of the Non-Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO).

  
  

• Member of the Standing Committee of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO).

  
  

• Member of the Lung Cancer Committee of the Chinese Anti-Cancer Association

• Vice Chairman of the Youth Committee of the Lung Cancer Special Committee of the Chinese Anti-Cancer Association

• Member of the Youth Committee of the Oncology Branch of the Chinese Medical Association

• Vice Chairman of the Tumor Chemotherapy Committee of the Chinese Health Science and Technology Promotion Association

• Vice Chairman of the Lung Cancer Committee of the Chinese Geriatric Health Care Association

• Member of the Standing Committee of the Difficult Oncology Committee of the China Medical Education Association

• He won the second prize of the National Science and Technology Progress Award (3rd), the first prize of the "Higher Education Science and Technology Progress Award" of the Ministry of Education (2nd), the 8th Shulan Medical Youth Award, etc

  
  

Tough soldiers, the first test of the front:

Multiple real-world studies unveiled at ESMO to help EGFR ex20ins mutant NSCLC treatment "a hand"

ESMO 2022 – Expert Reviews

Professor Wang Zhijie

Cancer Hospital, Chinese Academy of Medical Sciences

ESMO 2022 – Expert Reviews

Professor Wang Zhijie

Cancer Hospital, Chinese Academy of Medical Sciences

The development of targeted new drugs for the treatment of EGFR ex20ins mutation NSCLC has become a hot topic in recent years, from the traditional EGFR-TKI to Sunvozertinib reported at this year's ESMO ^conference

References:

1.

2.

3.

4.
Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
ASCO2022.
Abs 9115.

5.
Matching-Adjusted Indirect Comparison of Amivantamab vs.
Mobocertinib in EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer.
ISPOR2022.
Abs 115347.

6.
Amivantamab vs Real World (RW) Therapies for Advances Non-Small cell Lung Cancer(aNSCLC)with Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion Mutation (E20i) in Japan.
ESMO2022.
Abs 1115P.

7.
Amivantamab vs Real World (RW) Therapies in Japanese patients with Advanced Non-Small Cell Luna Cancer (aNSCLC) Epidermal Growth Factor Receptor (EGFR) Exon 20insertion.
ESMO2022.
Abs 1109P.

8.
Amivantamab compared with European,real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor (EGFR) Exon 20 insertion mutations (Exon20ins) after failure of platinum-based therapy.
ESMO2022.
Abs 1117P.

9.
An adiusted comparison of Amivantamab phase II data versus real-world clinical manaement in France of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC patients.
ESMO2022.
Abs 1122P.

10.
Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP).
ESMO2022.
Abs 1111P.

11.
Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP).
ESMO2022.
Abs 988P.

12.
Sunvozertinib in NSCLC patients with EGFR exon 20 insertion mutations.
ESMO2022.
Abs 987P.